A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years
Open Access
- 9 November 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 31 (3) , 543-555
Abstract
To evaluate the safety of peficitinib for the treatment of rheumatoid arthritis (RA) in Asian patients. Safety data from one Phase 2b, two Phase 3, and one open-label long-term extension study [dat...Keywords
Funding Information
- Astellas Pharma, Inc.
This publication has 37 references indexed in Scilit:
- Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb studyAnnals of the Rheumatic Diseases, 2016
- Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010Modern Rheumatology, 2015
- Analysis of Infections and All‐Cause Mortality in Phase II, Phase III, and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2014
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2014
- Age and Cancer RiskAmerican Journal of Preventive Medicine, 2014
- Janus kinase inhibitors in autoimmune diseasesAnnals of the Rheumatic Diseases, 2013
- The Japanese experience with biologic therapies for rheumatoid arthritisNature Reviews Rheumatology, 2010
- Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic ArthritisThe Journal of Rheumatology, 2010
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Therapeutic Strategies for Rheumatoid ArthritisNew England Journal of Medicine, 2004